These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 20412067)

  • 41. Pharmacotherapy for women's sexual dysfunction.
    Basson R
    Expert Opin Pharmacother; 2009 Jul; 10(10):1631-48. PubMed ID: 19527189
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vasoactive intestinal polypeptide as a neurotransmitter in the female genital tract.
    Ottesen B
    Am J Obstet Gynecol; 1983 Sep; 147(2):208-24. PubMed ID: 6137145
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Arousal disorders in women: complaints and complexities.
    Leiblum SR
    Med J Aust; 2003 Jun; 178(12):638-40. PubMed ID: 12797853
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Restoration of female genital vasocongestive arousal responses in young and aged rats.
    Beharry RKS; Hale TM; Heaton JPW; Shamloul R; Adams MA
    J Sex Med; 2008 Apr; 5(4):804-812. PubMed ID: 18221278
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Drugs in early clinical development for the treatment of female sexual dysfunction.
    Belkin ZR; Krapf JM; Goldstein AT
    Expert Opin Investig Drugs; 2015 Feb; 24(2):159-67. PubMed ID: 25376023
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Experimental models for the investigation of female sexual function and dysfunction.
    Min K; O'Connell L; Munarriz R; Huang YH; Choi S; Kim N; Goldstein I; Traish A
    Int J Impot Res; 2001 Jun; 13(3):151-6. PubMed ID: 11525313
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Topical alprostadil in the treatment of Female Sexual Arousal Disorder: a pilot study.
    Islam A; Mitchel J; Rosen R; Phillips N; Ayers C; Ferguson D; Yeager J
    J Sex Marital Ther; 2001; 27(5):531-40. PubMed ID: 11554216
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Emerging therapies for female sexual dysfunction.
    Segraves RT
    Expert Opin Emerg Drugs; 2003 Nov; 8(2):515-22. PubMed ID: 14662003
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment options for female sexual arousal disorder: part II.
    Feldhaus-Dahir M
    Urol Nurs; 2010; 30(4):247-51. PubMed ID: 20949811
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: a double-blind, placebo controlled study.
    Berman JR; Berman LA; Toler SM; Gill J; Haughie S;
    J Urol; 2003 Dec; 170(6 Pt 1):2333-8. PubMed ID: 14634409
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pelvic nerve injury negatively impacts female genital blood flow and induces vaginal fibrosis-implications for human nerve-sparing radical hysterectomy.
    Castiglione F; Bergamini A; Albersen M; Hannan JL; Bivalacqua TJ; Bettiga A; Benigni F; Salonia A; Montorsi F; Hedlund P
    BJOG; 2015 Oct; 122(11):1457-65. PubMed ID: 26179559
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Haemodynamics of pelvic nerve induced penile erection in the dog: possible mediation by vasoactive intestinal polypeptide.
    Andersson PO; Bloom SR; Mellander S
    J Physiol; 1984 May; 350():209-24. PubMed ID: 6747850
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.
    Althof S; Derogatis LR; Greenberg S; Clayton AH; Jordan R; Lucas J; Spana C
    J Sex Med; 2019 Aug; 16(8):1226-1235. PubMed ID: 31277966
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Vasculogenic female sexual dysfunction: vaginal engorgement and clitoral erectile insufficiency syndromes.
    Goldstein I; Berman JR
    Int J Impot Res; 1998 May; 10 Suppl 2():S84-90; discussion S98-101. PubMed ID: 9647967
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of neutral endopeptidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilat.
    Dalzell JR; Seed A; Berry C; Whelan CJ; Petrie MC; Padmanabhan N; Clarke A; Biggerstaff F; Hillier C; McMurray JJ
    Cardiovasc Ther; 2014 Feb; 32(1):13-8. PubMed ID: 24138103
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Topical alprostadil (PGE1) for the treatment of female sexual arousal disorder: in-clinic evaluation of safety and efficacy.
    Heiman JR; Gittelman M; Costabile R; Guay A; Friedman A; Heard-Davison A; Peterson C; Dietrich J; Stephens D
    J Psychosom Obstet Gynaecol; 2006 Mar; 27(1):31-41. PubMed ID: 16752874
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder.
    Basson R; McInnes R; Smith MD; Hodgson G; Koppiker N
    J Womens Health Gend Based Med; 2002 May; 11(4):367-77. PubMed ID: 12150499
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The complexities of female sexual arousal disorder: potential role of pharmacotherapy.
    Basson R
    World J Urol; 2002 Jun; 20(2):119-26. PubMed ID: 12107543
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Genital vascular responsiveness and sexual feelings in midlife women: psychophysiologic, brain, and genital imaging studies.
    van Lunsen RH; Laan E
    Menopause; 2004; 11(6 Pt 2):741-8. PubMed ID: 15543026
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vasoactive intestinal polypeptide (VIP) provokes vaginal lubrication in normal women.
    Ottesen B; Pedersen B; Nielsen J; Dalgaard D; Wagner G; Fahrenkrug J
    Peptides; 1987; 8(5):797-800. PubMed ID: 3432128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.